Recently, receptor tyrosine kinase inhibitors (TKIs) pazopanib and sunitinib have been used to treat metastatic ccRCC via suppressing the function of vascular endothelial growth factor and mechanistic target of rapamycin (mTOR), respectively. Here, MTOR is linked to nonpapillary renal cell carcinoma.